Impax Laboratories (IPXL)
Impax Laboratories Revenue Growth: 18.33%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
IPXL Revenue Growth Rankings
| Overall | 73rd percentile | 1137 of 4364 |
| Sector | 67th percentile | 146 of 456 in Healthcare |
| Industry | 72nd percentile | 5 of 18 in Drug Manufacturers - Major |
IPXL Revenue Growth Range, Past 5 Years
| Minimum | -66.40% | Mar 2011 |
| Maximum | 448.8% | Mar 2010 |
| Average | 94.75% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these IPXL related companies
IPXL News
Top 4 Small-Cap Stocks In The Drug Manufacturers-Major Industry With The Highest Profit Margin
May 23, 2:27AM Benzinga
May 23, 2:27AM Benzinga
Impax Laboratories Announces Voting Results from 2012 Annual Meeting of Stockholders
May 22, 4:05PM Business Wire
May 22, 4:05PM Business Wire
Auriga Reiterates a 'Buy' on Impax Laboratories (IPXL); Positive After Meetin with Management
May 14, 10:17AM Street Insider
May 14, 10:17AM Street Insider
Impax Laboratories to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
May 10, 9:00AM Business Wire
May 10, 9:00AM Business Wire
$IPXL forms bearish "Double Top" chart pattern. http://stks.co/3l1f
about 21 days ago by RecogniaEvents
about 21 days ago by RecogniaEvents
Needham & Company Maintains a 'Hold' on Impax Laboratories (IPXL); Clearing Q1 Hurdle; Regulatory Clouds Remain
May 02, 9:02AM Street Insider
May 02, 9:02AM Street Insider
$IPXL Impax Labs falls on weak sales, new FDA warning
http://stks.co/3bjj $$
about 29 days ago by stockspot
about 29 days ago by stockspot
News related to $IPXL, currently -1.8% since open: 'Endo Pharma turns 1Q loss on $100M pre-tax charge' http://stks.co/3bg7
about 29 days ago by TradeBot
about 29 days ago by TradeBot
Listen to $IPXL Q1 2012 earnings call - live at 11:00 AM, ondemand after - http://stks.co/3bTc
about 29 days ago by earningscast
about 29 days ago by earningscast
Impax Laboratories Reports Adjusted First Quarter 2012 EPS of $0.52; GAAP EPS of $0.18
May 01, 7:00AM Business Wire
May 01, 7:00AM Business Wire
Auriga Maintains a 'Buy' on Impax Laboratories (IPXL); Generic Adderall XR Sales In-Line
Apr 26, 10:45AM Street Insider
Apr 26, 10:45AM Street Insider
Impax Laboratories Confirms Patent Challenge Relating to Generic GRALISEĀ® 300 mg and 600 mg
Apr 12, 9:20AM Benzinga
Apr 12, 9:20AM Benzinga
Impax Laboratories Schedules Conference Call and Webcast for First Quarter 2012 Financial Results
Apr 04, 8:00AM Business Wire
Apr 04, 8:00AM Business Wire
Big weekend Market Newsletter http://stks.co/3B8T also includes watch list stocks $ALR, $BOE, $EGHT, $GGP, $IPXL, $TRLG
about 58 days ago by StockTiger
about 58 days ago by StockTiger
Comprehensive Market Newsletter 60+ charts http://stks.co/3AaV plus additions to watch list $ALR, $BOE, $EGHT, $GGP, $IPXL, $TRLG
about 59 days ago by StockTiger
about 59 days ago by StockTiger
Impax Laboratories Enters Into Development, Supply and Distribution Agreement with TOLMAR
Mar 26, 8:03AM Benzinga
Mar 26, 8:03AM Benzinga
Impax Laboratories Enters Into Development, Supply and Distribution Agreement with TOLMAR, Inc.
Mar 26, 8:00AM Business Wire
Mar 26, 8:00AM Business Wire
$IPXL http://stks.co/2uy4 Consolidating wedge, over 23.80 has MM to 28
about 74 days ago by harmongreg
about 74 days ago by harmongreg
Canaccord Genuity Reiterates a 'Buy' on Impax Laboratories (IPXL); Our Top Small Cap Pick is Catalyst Heavy
Mar 14, 8:59AM Street Insider
Mar 14, 8:59AM Street Insider
RT @BlueFielder $IPXL set to run like hell < nice Hammer today, thanks for that.
about 86 days ago by 1nvestor
about 86 days ago by 1nvestor
Canaccord Genuity Maintains a 'Buy' on Impax Laboratories (IPXL); Thesis Unchanged After Meetings With Management
Mar 05, 10:11AM Street Insider
Mar 05, 10:11AM Street Insider
Top 4 Small-Cap Stocks In The Drug Manufacturers-Major Industry With The Highest Revenue
Mar 02, 2:59AM Benzinga
Mar 02, 2:59AM Benzinga
Listen to $IPXL Q4 2011 earnings call - live at 11:00 AM, ondemand after - http://stks.co/2av6
about 92 days ago by earningscast
about 92 days ago by earningscast
Relatively strong, under the radar earnings reports from $IPXL $VSI $MENT this morning
about 92 days ago by ivanhoff
about 92 days ago by ivanhoff
Spinning Top to end the week, now a range to play. Let it show its hand on 2/27 first for a new pos. $IPXL http://chart.ly/tff9hrf
about 94 days ago by 1nvestor
about 94 days ago by 1nvestor
@cowboy1 $IPXL is scheduled to report earnings soon so I would be careful with that one.
about 97 days ago by TazTrader
about 97 days ago by TazTrader
$IPXL is 5.0 pct. up since open on unusual high volume and 0.1 pct. up since close.
about 111 days ago by TradeBot
about 111 days ago by TradeBot
$IPXL 200 Day SMA Cross - Price crossed below 200 day SMA (20.5349). Confirmed by volume.
about 111 days ago by TradeIdeasQuant
about 111 days ago by TradeIdeasQuant
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| IPXL | 21.15 | -0.28 | -1.31% | 1.432B |
| IPW | 22.78 | +0.00 | +0.00% | |
| IPU | 15.00 | -0.22 | -1.43% | |
| IPT | 0.2112 | +0.01 | +3.53% | 5.155M |
| IPSU | 6.34 | -0.01 | -0.16% | 77.60M |
| IPG | 10.71 | -0.28 | -2.55% | 4.903B |
| IPF | 14.84 | +0.00 | +0.00% | |
| IPCM | 35.12 | -0.32 | -0.90% | 585.47M |
| IPCI | 2.96 | +0.00 | +0.00% | 47.09M |
| IPCC | 54.06 | -0.55 | -1.01% | 644.40M |